Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280849 | 1.00 | — | — | |
| SCHEMBL21478685 | 1.00 | ODC1 (0.41) | ODC1CA2CYP3A4TSHRDDAH1 | |
| SCHEMBL12349346 | 1.00 | ODC1 (0.41) | ODC1CA2CYP3A4TSHRDDAH1 | |
| SCHEMBL12349367 | 1.00 | ODC1 (0.41) | ODC1CA2CYP3A4TSHRDDAH1 | |
| SCHEMBL9863417 | 1.00 | ODC1 (0.41) | ODC1CA2CYP3A4TSHRDDAH1 | |
| SCHEMBL24753245 | 0.97 | ODC1 (0.39) | ODC1CA2CYP3A4TSHRDDAH1 | |
| Hydrochloric Acid SCHEMBL4701964 | 0.97 | ODC1 (0.39) | ODC1CA2CYP3A4TSHRDDAH1 | |
| SCHEMBL5936431 | 0.92 | CA2 (0.38) | CA2CYP3A4TSHRDDAH1NFKB1 | |
| SCHEMBL19591114 | 0.92 | ODC1 (0.39) | ODC1CA2CYP3A4TSHRDDAH1 | |
| SCHEMBL18391516 | 0.92 | CA2 (0.38) | CA2CYP3A4TSHRDDAH1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-01 | — | — | US | disclosed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-11299635-B2 | Bis-Azo colorants for use as bluing agents | MILLIKEN & COMPANY (US) | 2022-04-12 | — | — | US | disclosed |
| US-10876079-B2 | Bis-azo colorants for use as bluing agents | THE PROCTER & GAMBLE COMPANY (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20200225215-A1 | SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION | 2020-07-16 | — | — | US | disclosed |
| US-10653780-B2 | Amino lipids and methods for the delivery of nucleic acids | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-05-19 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110097720-A1 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2010151906-A2 | BIS-AZO COLORANTS FOR USE AS BLUING AGENTS | MILLIKEN & COMPANY (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100324120-A1 | LIPID FORMULATION | BANK OF AMERICA, N.A. | 2010-12-23 | — | — | US | disclosed |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | ALNYLAM PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-7632682-B2 | Anthraquinone colorant compositions and methods for producing the same | MILLIKEN & COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
| EP-1828314-A2 | IMPROVED ANTHRAQUINONE COLORANT COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | Milliken & Company (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006062970-A2 | IMPROVED ANTHRAQUINONE COLORANT COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MILLIKEN & COMPANY (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060117499-A1 | Anthraquinone colorant compositions and methods for producing the same | MILLIKEN & COMPANY | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ODC1 3205/4885CA2 4453/4885CYP3A4 4794/4885 |
| US-20100324120-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | ODC1 2438/4885CA2 3223/4885CYP3A4 2603/4885 |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, SGMS1, PHOSPHO1 | ODC1 2393/4885CA2 4688/4885CYP3A4 3899/4885 |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | LDLR, SNRPE, SARNP | ODC1 4422/4885CA2 3610/4885CYP3A4 4884/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ODC1 3205/4885CA2 4453/4885CYP3A4 4794/4885 |
| US-10653780-B2 | Amino lipids and methods for the delivery of nucleic acids | NSUN3, SARNP, LDLR | ODC1 3590/4885CA2 3725/4885CYP3A4 4881/4885 |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | SGMS2, APOB, PHOSPHO1 | ODC1 2538/4885CA2 3202/4885CYP3A4 3740/4885 |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ODC1 3205/4885CA2 4453/4885CYP3A4 4794/4885 |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | KIF5A, KIF5C, KIF11 | ODC1 4171/4885CA2 3977/4885CYP3A4 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.